Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT
Recruiting now · Not applicable
Conditions studied: Moxibustion, Hematopoietic Stem Cell Transplantation, Hemorrhagic Cystitis, Prevention
In brief
This study was a prospective, multicenter, randomized controlled clinical study planned to recruit 266 hematological patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT), who were randomly divided into two groups according to gender, type of transplantation, and type of primary disease. The control group was treated conventionally, and the experimental group increased moxibustion of Zhongji, Guanyuan and Qihai for 30 min qd starting on the first day after HSCT was performed until the 14th day after transplantation. Urine routine tests were performed at the time of admission, +1d, and +14d, and urine BK virus, JC virus, and adenovirus were tested at four time points, namely, +1d, +14 days, onset of hematuria symptoms, and remission of HC, respectively; routine urine tests were performed once every 7 days for all patients within 100days. For patients with Hemorrhagic cystitis (HC), daily severity grading, pain scoring, cystitis symptom scoring, use of antispasmodic and analgesic medications, and major TCM evidence were recorded with the aim of evaluating the efficacy of moxibustion in the prevention of HC in this patient population.
Key facts
- Study ID
- NCT06198517
- Run by
- Yi Zhang
- People needed
- 266
- Starts
- 2024-03-21
- Expected to finish
- 2026-09-30
- Last updated by the study team
- 2026-03-12
Who can join
Age: 14 and older, up to 60. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients are fully aware of the study, participate voluntarily and sign the informed consent form (ICF);
- Age: 14-60 years;
- Patients with pernicious blood diseases undergoing allo-HSCT using the MAC protocol or patients with severe aplastic anemia (Severe aplastic anemia; severeaplasticanimin, SAA) undergoing allo-HSCT;
You may not qualify if…
- refuse to participate in this clinical study;
- The corresponding skin at the moxibustion site is broken or sensitive;
- allo-HSCT pretreated with the RIC program;
Where it is running
- Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou — Zhengzhou, Henan, China (enrolling)
- Yi Zhang — Wuhan, Hubei, China (enrolling)
- Hematology Department, The First People's Hospital of Yunnan — Kunming, Yunnan, China (enrolling)
- Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou — Hangzhou, Zhejiang, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.